Natus Medical Incorporated (NTUS) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Natus Medical Incorporated (NTUS) Healthcare & Pipeline Overview

Natus Medical Incorporated delivers medical device solutions for diagnosing and treating central nervous and sensory system disorders globally. With a focus on newborn care, hearing impairment, and neurological conditions, the company offers screening, detection, and monitoring technologies, positioning itself as a key player in the medical devices sector.

What Is the Investment Thesis for NTUS?

Natus Medical Incorporated presents a mixed investment thesis. The company's established position in the medical device market, particularly in newborn care and neurodiagnostics, provides a stable revenue base. Its gross margin of 57.8% indicates strong pricing power. However, a high P/E ratio of 85.0 suggests the stock may be overvalued relative to its earnings. The company's beta of 0.23 indicates low volatility compared to the market. Growth catalysts include expanding its product offerings and penetrating emerging markets. Potential risks include increasing competition and regulatory changes in the healthcare industry. Investors should carefully weigh the valuation against growth prospects and potential headwinds.

Based on FMP financials and quantitative analysis

NTUS Key Highlights

Gross Margin of 57.8% demonstrates strong pricing power in the medical device market.

• P/E Ratio of 85.0 indicates a potentially high valuation relative to earnings.
• Beta of 0.23 suggests lower volatility compared to the broader market.
• Focus on newborn care and neurodiagnostics provides a stable revenue base.
• Global presence allows for diversification and access to multiple markets.

Who Are NTUS's Competitors?

NTUS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NTUS's Key Strengths?

Strong market position in newborn care and neurodiagnostics.

• Comprehensive product portfolio.
• Global presence.
• Established relationships with key customers.

What Are NTUS's Weaknesses?

High P/E ratio may indicate overvaluation.

• Dependence on specific product lines.
• Exposure to regulatory changes in the healthcare industry.
• Competition from larger medical device companies.

What Could Drive NTUS Stock Higher?

Potential for new product launches in the neurodiagnostics space.

• Expansion into emerging markets with growing healthcare infrastructure.
• Strategic partnerships with healthcare providers to enhance service offerings.

What Are the Key Risks for NTUS?

Rich valuation — a P/E of 85.0 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Increased competition from established medical device companies.
• Regulatory changes impacting the approval and reimbursement of medical devices.
• Economic downturn affecting healthcare spending.
• Technological obsolescence requiring continuous innovation.

What Are the Growth Opportunities for NTUS?

• Expansion in Emerging Markets: Natus can expand its presence in emerging markets, such as Asia-Pacific and Latin America, where healthcare infrastructure is developing and demand for medical devices is increasing. These markets offer significant growth potential due to their large populations and rising healthcare expenditure. Successfully penetrating these markets could significantly boost Natus's revenue and market share. Timeline: Ongoing.
• New Product Development: Investing in research and development to create innovative medical devices and solutions can drive future growth. Focusing on areas such as advanced neurodiagnostics, telemedicine, and remote patient monitoring can capitalize on emerging trends in healthcare. Introducing new products can attract new customers and increase revenue from existing customers. Timeline: Ongoing.
• Strategic Acquisitions: Acquiring complementary businesses and technologies can expand Natus's product portfolio and market reach. Targeting companies with innovative technologies or strong market positions in adjacent areas can create synergies and accelerate growth. Strategic acquisitions can also provide access to new customer segments and geographic markets. Timeline: Ongoing.
• Telemedicine Integration: Integrating its medical devices with telemedicine platforms can expand Natus's reach and improve patient access to care. Telemedicine is becoming increasingly popular, especially in rural areas and for patients with mobility issues. By offering telemedicine-enabled solutions, Natus can tap into this growing market and differentiate itself from competitors. Timeline: Ongoing.
• Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare providers can create new opportunities for Natus. Partnering with these organizations to offer comprehensive solutions and services can improve patient outcomes and increase revenue. These partnerships can also provide valuable insights into customer needs and market trends. Timeline: Ongoing.

What Are NTUS's Competitive Advantages?

• Specialized product portfolio focused on niche markets.
• Strong brand reputation in newborn care and neurodiagnostics.
• Established relationships with key customers in the healthcare industry.
• Proprietary technologies and intellectual property.

What Does NTUS Do?

Natus Medical Incorporated, originally founded as ALGOTEK Instruments, Inc. in 1987 and renamed in 1988, is a global provider of medical device solutions focused on the diagnosis and treatment of patients with central nervous and sensory system disorders. Headquartered in Middleton, Wisconsin, the company offers a comprehensive portfolio of products and technologies used for screening, detection, treatment, monitoring, and tracking of common medical ailments. These include solutions for newborn care, addressing conditions such as jaundice and brain injury; hearing impairment, providing hearing assessment and instrument fitting solutions; neurological and neurosurgical treatments, offering electroencephalography and intra-operative monitoring solutions; epilepsy, sleep disorders, and neuromuscular diseases. Natus also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, along with software systems for managing and tracking disorders and diseases for public health laboratories. The company's products are utilized in various settings, including university medical centers, public and private hospitals, physician offices, clinics, and research laboratories. Natus aims to improve patient outcomes through innovative medical technologies and comprehensive solutions.

What Products and Services Does NTUS Offer?

• Develops and markets medical devices for diagnosing and treating central nervous and sensory system disorders.
• Offers solutions for newborn care, including jaundice management and brain injury products.
• Provides hearing assessment and screening solutions for hearing impairment.
• Offers neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology.
• Provides software systems for managing and tracking disorders and diseases for public health laboratories.
• Offers electroencephalography, long term monitoring, and intra-operative monitoring solutions.
• Provides balance assessment systems to evaluate patients with balance disorders.
• Offers NICVIEW, a live streaming video for families with babies in the NICU.

How Does NTUS Make Money?

• Develops and manufactures medical devices and software solutions.
• Sells products directly to hospitals, clinics, and other healthcare providers.
• Generates revenue through product sales and service contracts.
• Invests in research and development to create new and innovative products.

What Industry Does NTUS Operate In?

Natus Medical Incorporated operates in the medical device industry, which is characterized by continuous innovation and increasing demand for advanced diagnostic and treatment solutions. The industry is driven by factors such as an aging population, rising prevalence of chronic diseases, and technological advancements. The competitive landscape includes major players in medical devices and specialized companies focusing on neurodiagnostics and newborn care. Natus's focus on specific niches within this market allows it to maintain a competitive edge through specialized products and services. The global medical devices market is projected to reach significant growth in the coming years, driven by increasing healthcare expenditure and technological advancements.

Who Are NTUS's Key Customers?

• University medical centers
• Public and private hospitals
• Physician offices and clinics
• Research laboratories

Company Profile

Natus Medical Incorporated operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Pleasanton, US. The company is led by CEO Jonathan Kennedy. NTUS has traded publicly since 2001.

How Natus Medical Incorporated Is Valued

Relative to its peer group, NTUS's quantitative score of 50/100 is below the peer average of 80/100.

Return on equity for Natus Medical Incorporated stands at 3.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.3%, showing how much profit it generates from its asset base. NTUS trades at a trailing price-to-earnings ratio of 84.98, above the Healthcare sector average of ~23x. A current ratio of 2.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.2%, the inverse of the P/E and a quick read on earnings relative to price.

Natus Medical Incorporated has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 61.5% above estimates on average.

NTUS Financials

NTUS Latest News

No recent news available for NTUS.

NTUS Analyst Consensus

NTUS MoonshotScore

NTUS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources